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Abstract: Regulatory T cells (Tregs) are essential for the maintenance of tolerance to self and non-self
through cell-intrinsic and cell-extrinsic mechanisms. Peripheral Tregs survival and clonal expansion
largely depend on IL-2 and access to co-stimulatory signals such as CD28. Engagement of tumor
necrosis factor receptor (TNFR) superfamily members, in particular TNFR2 and DR3, contribute to
promote peripheral Tregs expansion and sustain their survival. This property can be leveraged to
enhance tolerance to allogeneic transplants by tipping the balance of Tregs over conventional T cells
during the course of immune reconstitution. This is of particular interest in peri-transplant tolerance
induction protocols in which T cell depletion is applied to reduce the frequency of alloreactive T cells
or in conditioning regimens that allow allogeneic bone marrow transplantation. These conditioning
regimens are being implemented to limit long-term side effects of continuous immunosuppression and
facilitate the establishment of a state of donor-specific tolerance. Lymphopenia-induced homeostatic
proliferation in response to cytoreductive conditioning is a window of opportunity to enhance
preferential expansion of Tregs during homeostatic proliferation that can be potentiated by agonist
stimulation of TNFR.
Keywords: regulatory T cells; lymphopenia; homeostatic proliferation; transplantation; TNF/TNF
receptors; graft-versus-host disease; graft rejection
1. Introduction
1.1. The Role of Regulatory T Cells in Transplantation
The initial description of T cells exhibiting suppressive function is attributed to Nishizuka and
coworkers. Neonatal thymectomy at day 3 of age, but not at day 7 or later, induced autoimmune
disease [1]. In the late 1980s, it was discovered that non-depleting monoclonal antibodies targeting
co-receptor molecules, namely CD4, could lead to long-term acceptance of allografts in mice [2,3].
That state of immune tolerance was dependent on CD4+ T cells, and it could be induced in new
cohorts of T cells, a process known as infectious tolerance [4,5]. Those CD4+ T cells stimulated with
alloantigens acquired a non-responsive state that could transfer tolerance to the same alloantigen present
in third-party recipients [6]. In 1995, Sakaguchi and coworkers identified a subpopulation of CD4+ T
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cells that exhibited constitutive expression of the IL-2R alpha subunit (CD25) and that were termed
regulatory T cells (Tregs) [7,8]. The adoptive transfer of CD4+CD25+ T cells prevented autoimmune
disease development induced by CD4+CD25− T cells [7], and the suppressive function was defined
later as dependent on the expression of transcription factor forkhead box P3 (Foxp3) [9]. Later, it was
shown that the antibody-induced transplantation tolerance was also mediated by CD4+CD25+ cells [10].
Those regulatory cells were demonstrated to seed tolerated allografts, protecting them from rejection [11].
Golshayan et al. showed that in vitro expanded alloantigen-specific Tregs cell clones provide efficient
adjuvant therapy to prolong allograft survival [12].
Among Foxp3+ Treg cells, some of them are generated in the thymus (tTreg) while others are
induced from uncommitted T cells in the periphery (pTreg) when activated in the presence of TGF-β
and IL-2 [13]. pTreg cells are essential in the control of inflammation at the epithelial barriers (gut and
lung) [14] and in the modulation of persistent chronic inflammation in infectious diseases [15]. In these
two scenarios, Tregs dampen inflammation to limit tissue damage and the subsequent immune
pathology [16]. These regulatory T cells are also essential to counterbalance the pathogenic allogeneic
immune responses in transplantation [11,17,18].
In vitro artificially differentiated Tregs (so called, in vitro-induced Tregs or iTregs) have been the
subject of intense research in the clinical arena for their promising therapeutic activity in exacerbated
inflammatory diseases, such as autoimmunity, prevention of graft-versus-host disease, graft rejection,
and chronic persistent infection. This name refers to all Tregs differentiated ex vivo from naïve T
cells using different methodologies such as exposure to signal 1 (anti-CD3)/signal 2 (anti-CD28) in
the presence of TGF-β and IL-2 to promote their clonal expansion. However, iTregs lack a proper
epigenetic programing and, as a result, tend to be unstable and lose Foxp3 expression [19]. Besides the
classical populations of Foxp3+ Tregs of lymphoid organs, an emerging diversity of tissue-resident
Tregs populations distributed throughout the body and detected in the tumor microenvironment has
been identified. It appears that they can gain specific transcription factors typical of different pathogenic
T cell subsets and adopt similar migration patterns to follow them to the sites of inflammation where
they can modulate in situ the course of the immune reaction [20]. A particular Treg population with
specific anatomic preferences is T follicular regulatory (Tfr) cells that have the unique ability to migrate
to B cell follicles where they regulate germinal center reaction and humoral immune responses [21].
The number of Treg cells and their suppressive functional activity are of paramount importance
for the maintenance of normal homeostasis of the immune system. Tregs differentiation and survival
depends on soluble and membrane-bound signals delivered by nearby immune cells and stroma cells
of lymphoid and non-lymphoid tissues [14,17,22]. An outlook of the cell-intrinsic and cell-extrinsic
mechanisms mediated by Tregs is depicted in Figure 1.
1.2. T Cell Depletion in Peri-Transplant Regimens and Allogeneic Bone Marrow Transplantation to Promote
Long-Term Survival of Allografts
Current immunosuppression effectively prevents and reverses acute rejection episodes;
however, the long-term survival of transplanted organs has not improved significantly in the last
two decades. This is in part due to the failure of immunosuppressive drugs to prevent chronic
rejection and the intrinsic toxic side effects of the long-term administration of immunosuppression that
gradually deteriorate graft function of the transplanted organ resulting in end-stage disease [23,24].
The other clinical scenario is allogeneic bone marrow transplantation for the treatment of malignancies
or the induction of transplantation tolerance that requires cytoreductive-conditioning regimens for the
successful engraftment of donor hematopoietic cells. In order to tackle these hurdles, tolerance induction
based on peri-transplant T cell depletion or conditioning of the host with low-dose irradiation and
co-stimulatory blockade have been put forward to minimize immunosuppressants, which are otherwise
necessary for the maintenance of graft survival in the long-term [25,26]. In transplantation, the use
of polyclonal rabbit serum against thymocytes (rATG) or the use of alemtuzumab monoclonal
antibody (anti-CD52, CAMPATH-1), besides irradiation, are the main common approaches to reduce
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the frequency of alloreactive T cells [27,28]. These approaches, however, induce lymphopenia,
which stimulates homeostatic proliferation and restoration of the normal lymphocyte counts in the
peripheral compartments of secondary lymphoid organs. This proliferative response converts naïve
T cells into memory T cells with increased cytotoxic capacity that then become resistant to current
immunosuppressive regimens, including CTLA-4.Ig-mediated co-stimulation blockade [27,29,30].
Henceforth, we will refer as T cell repertoire resistant to costimulatory blockade to the set of T
cells arisen after T cell depletion in response to lymphopenia that repopulate the peripheral T
cell compartment.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 1 of 23 
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central role in maintaining immune self-tolerance and preventing autoimmune diseases. Tregs with 
suppressive function, characterized by expression of the forkhead/winged-helix transcription factor 
Foxp3 (Foxp3), are generated either in the thymus (tTregs) or in the periphery (pTregs), the latter from 
naïve T cells under the influence of TGF-β and IL-2. The following cell-extrinsic and cell-intrinsic 
Tregs suppressive mechanisms operate on effector T cells, NK cells, as well as on antigen-presenting 
Figure 1. Suppressive mechanisms of regulatory T cells (Tregs). Regulat r cells (Tregs) play a central
role in maintaining immune self-tolera ce and prev nting autoimm ne diseases. Tregs with suppressive
function, characterized by expression of the fo khead/winged-helix transcriptio factor Foxp3 (Foxp3),
are generated either in the thymus (tT egs) or in the periphery ( Tregs), the latter from naïve T cells
under the i fluenc of TGF-β and IL-2. The following cell-extrinsic and cell-intri si Tregs uppressive
mechanisms operate on effector T cells, NK cells, as well a on antigen-presenting c lls (APC) to regulate
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their function: (1) CTLA-4 engagement of CD80/CD86 induces the expression of indoleamine
2,3-dioxygenase (IDO) enzyme. This enzyme degrades tryptophan, which is an essential amino
acid required for T cell proliferation and survival. The catabolism of this amino acid gives rise to toxic
metabolites that inhibit effector T cell function leading to impaired humoral- and cellular-mediated
immune responses. (2) An additional cell extrinsic mechanism of suppression is mediated by CTLA-4
that it is constitutively expressed on Tregs. CTLA-4 expressed on Tregs suppresses CD28-mediated T cell
activation by a dual mechanism: competing with CD28 for binding to CD80/CD86 (B7.1/B7.2) ligands and
induction of CD80/CD86 transendocytosis to shut down co-stimulation. (3) Under resting conditions,
high-affinity IL-2R (IL-2Rαβγ) is constitutively expressed on Tregs that require basal amounts of IL-2
for their survival. Tregs suppress T cell effector function by limiting the availability of IL-2 produced by
activated T cells right after receiving co-stimulatory signal 2, which is essential for autocrine-mediated
proliferation. Tregs do not produce IL-2 themselves, although they can compete very efficiently for this
cytokine, inducing IL-2 starvation and apoptosis of neighboring effector cells. (4) Another suppressor
activity of Tregs is mediated via the secretion of immunosuppressive cytokines such as IL-35, IL-10,
and TGF-β. IL-35 is a heteromeric member of the IL-12 family composed of p35 (IL-12A) and Ebi3
(Epstein–Barr virus-induced gene 3) subunits, which, together with IL-10, cooperatively suppresses the
functional activity of conventional T cells. The other key cytokine in Tregs function is TGF-β which is
synthetized as a pro-TGF-β precursor, a heterodimer composed of latency-associated protein (LAP)
and mature TGF-β. After signal peptide removal, TGF-β precursor is processed by proteolytic cleavage
(furin) to generate the mature polypeptide from the pro-domain. Mature TGF-β remains non-covalently
associated to LAP. Latent TGF-β may be secreted alone, but in this form is inactive until it is released
from LAP. GARP (glycoprotein A repetitions predominant) is a membrane-bound protein that transports
and anchors latent TGF-β to the Tregs cell surface and can inhibit effector function upon cell-to-cell
contact with nearby effector T cells expressing the receptor for this cytokine. Active TGF-β binds to
type II TGF-β receptor leading to phosphorylation and recruitment of TGF-β receptor type I into a
heteromeric receptor complex. Mature TGF-β can act either on Tregs themselves (autocrine manner) or
target cells in their vicinity (paracrine manner). (5) Adenosine (ADO) is a purine nucleoside produced
via enzymatic hydrolysis of extracellular ATP by the coordinated action of nucleoside triphosphate
diphosphohydrolase CD39 and the ecto-5′-nucleotidase CD73, two membrane-bound proteins of Tregs.
Adenosine interacts with distinct cell surface G-protein-linked receptors expressed on a variety of
immune cells. Among these receptors, effector T cells and NK cells express A2A receptors, whereas A2B
receptors are found on granulocytes. The engagement of adenosine receptors by adenosine inhibits
NK cells, effector T cells functions, and induces a tolerogenic phenotype on APC. (6) Tregs can also
behave as cytotoxic cells killing target cells (APC, NKs, and T cells) through the secretion of perforin
and granzymes, and the subsequent induction of apoptosis. (7) Competition for signal 4 by tumor
necrosis factor receptor (TNFR) endocytosis: CD27 expressed on the surface of Tregs binds to CD70
on APCs and this leads to CD70/CD27 complex internalization into the APCs, preventing CD70 from
binding CD27 present in surrounding cells. Red dotted arrow: Perforin/granzyme cytolytic pathway,
blue dotted arrow: cytokine interaction with its receptor, green dotted arrow: enzymatic conversion of
ATP to AMP and red dotted arrow: enzymatic conversion of AMP to adenosine.
American physiologist Walter Cannon was the first scientist that coined the term homeostasis to
define the tendency of an organism to restore its original status in the face of unexpected disturbances.
Cell numbers are kept constant despite alterations inflicted by the action of different inflammatory
threats [31]. The principle of immune homeostatic regulation is competition for limited resources of the
remaining cells left within an emptied niche when T cell numbers are reduced after lymphocyte depletion
leading to lymphopenia [32]. Under non-inflammatory conditions, homeostasis of naïve and memory
T cells is under independent regulation [32]. The separation of cellular niches ensures simultaneously
efficient protection against common pathogens, the maintenance of immunological T-cell memory,
and a reservoir of T cell repertoire diversity capable of coping with new antigenic threats [33].
The accomplishment of complete immune repopulation after lymphopenia induction (T cell
depletion or irradiation) is still an unmet goal in many of the clinical settings such as in autologous or
allogeneic hematopoietic stem cell transplantation (HSCT) and cancer chemotherapy. In both humans
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and mice, lymphopenia creates an immunological niche of emptied space that is readily repopulated.
This situation leads to conversion of residual naïve T cells into memory T cells, which, along with residual
memory T cells resistant to T cell depletion, would expand in the periphery giving rise to an oligoclonal
T cell repertoire with limited T cell receptor (TCR) diversity and prone to autoimmunity [34–36].
The repopulation of lymphocytes in lymphopenic environments depends on the relative contribution
of two orchestrating reconstitution pathways. The first path is peripheral expansion of naïve,
effector/memory residual T cells that remain after T cell depletion that proliferate actively in response
to antigenic stimuli (such as commensal bacteria of the gut), as well as to freely available abundant
homeostatic cytokines such as IL-7, IL-2, and IL-15. In the presence of an active thymus, this initial
burst of memory T cell expansion is followed by the generation of a wave of recent thymic emigrants
via thymopoiesis and their export to the peripheral pool [37,38]. T cell repopulation in response to
lymphopenia revealed the existence of two types of lymphopenic environments: severe lymphopenia
typical of immunodeficient mice (nude mice, SCID mice, Rag1 KO mice, or lethally irradiated mice)
and mild lymphopenia that occurs in normal antibody-mediated T cell depleted mice or in sub-lethally
irradiated mice [28,29,31,32]. In severe lymphopenia, an intense, fast, spontaneous homeostatic
proliferation predominates, which is IL-7-independent and driven by antigens derived from commensal
bacteria of the gut. Cell division occurs every 6–8 h and permits the reconstitution of an oligoclonal low
TCR affinity T cell repertoire cross-reactive with endogenous antigens (self-antigens and commensal
microflora) and prone to induce tissue inflammation and autoimmune disease [28,29]. In slow
homeostatic proliferation, the immune system faces less severe lymphopenia, often induced through
selective depletion of T lymphocytes via rATG or alemtuzumab, or after a sublethal dose of irradiation,
in the presence of an intact thymus. In this scenario, a slow homeostatic proliferation rate predominates
in response to this type of mild lymphopenia. It is IL-7-dependent, TCR-independent, and cell
division occurs in secondary lymphoid organs every 24–36 h [37]. Contrary to fast proliferation,
slow proliferation is more beneficial for the host as it regenerates a more diverse TCR repertoire
composed predominantly of naïve T cells [29]. One limitation of these T cell repertories regenerated
after lymphopenia inductive regimens is that they become highly cytotoxic against donor cells, and the
frequency of memory-like T cells resistant to conventional immunosuppression and co-stimulation
blockade is high [39]. Therefore, these clinical interventions in the early post-transplant stage may
predispose patients to rejection due to a misbalance of naïve/memory T cells and Treg cells in the
newly developed repertoire [27,30]. These approaches can trigger a serious autoimmune-prone T
cell repertoire particularly in adults and in the elderly, in which thymic output is physiologically
compromised to some extent [40]. Although thymic export of recent thymic emigrants decays gradually
from puberty onwards to adulthood, T cell counts in secondary lymphoid organs remain constant.
This suggests that thymic-independent pathways of T cell regeneration that rely on homeostatic
proliferation are in place in adults to compensate for the progressive deficiency in thymic output,
although this comes at the expense of loss of TCR diversity [40]. In aging people, this scenario creates
a bias of the T cell repertoire that predominantly favors T cells exposed to continuous stimulation
by the antigenic milieu of the host at the time of T cell repopulation and the loss of TCR diversity.
Residual naïve T cells remaining after T cell depletion bearing TCRs for Ags that were absent at the
time of T cell reconstitution are barely represented [41] (Figure 2).
The initial, spontaneous, fast peripheral T cell expansion due to active proliferation in response to
lymphopenia takes advantage of the presence of an abundant amount of freely available cytokines
in the internal milieu and plenty of antigen-driven signals. This abnormal proliferation needs to be
regulated at early time points to control the undesirable side effects of a newly generated oligoclonal T
cell repertoire mainly composed of effector/memory T cells resistant to immunosuppression in the
recipient of an allograft [28,41]. In patients with sufficient thymic function, de novo T cell production
and export of recent thymic emigrants (naïve T cells and tTregs) restricts the course of peripheral
expansion of memory-like T cells and, thus, helps to restore a diverse T cell repertoire not prone to
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autoimmunity. This regenerated immune system is fully proficient and operative to recognize and
fight infectious threats [33].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 1 of 23 
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to T cell depleti Rabbit polyclonal anti-th mocyte globin ATG (rATG) and alem uzumab are
the two biologics most freq ently used in T cell depleting protocols to reduce the frequency of
alloreactive T cells from the T cell repertoire of patients immediately after transplantation. This clinical
intervention aims at preventing early episodes of acute graft rejection and permits post-transplant
tapering of immunosuppression. Whole-body irradiation of the recipient is also applied in allogeneic
bone marrow transplantation to allow the engraftment of donor stem cells that also depletes the
peripheral compartment of T cells. In the depicted hypothetical model, repopulation of the peripheral
T cell repertoire occurs via thymus output of recent thymic emigrants and peripheral expansion of
predom n ly residual effector/memory T cells along with a very sm ll populat on of naïve T cells
resistant to T cell depletion or irradiation. Two waves of T cell r population occur in response to
lymphopenia to restore a depleted lymphoid peripheral compartment rich in growth factors and space to
repopulate. First, the few remaining residual naïve T cells and more abundant residual effector/memory
T cells quickly proliferate (fast spontaneous proliferation). After this initial repopulation wave, a second
wave of slow T cell proliferation starts. In the presence of an intact thymus, recent thymic emigrants
actively exit the thymus and enter the peripheral compartment, in which they are converted into
effector/memory T cells while replicating. T is wave of thymic output also contains thymic Tregs
(tTregs) that, along with pTregs converted from naïve T cells under the influence of TGF-β, configure the
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Tregs peripheral pool. Thymic emigration is paramount to regulate the rate of recovery of the peripheral
T cell pool through a process termed lymphopenia-induced slow proliferation. During this phase of
in vivo T cell reconstitution, expansion of Tregs can be favored by the administration of IL-2/anti-IL-2
immune complexes that, combined with agonist signaling through TNFR, provides an advantage to
Tregs over alloreactive T cells and tips the balance towards regulation instead of aggressive response.
Through this approach of selective expansion of Tregs during T cell repopulation, a more effective
modulation of effector alloreactive T cell responses can be achieved in conditioning regimens that
require mild T cell depletion in the peri-transplant period. The predominant pathway in the presence
of thymic activity is slow proliferation that restores a complete T cell repertoire with sufficient TCR
diversity and protects from autoimmunity. Red zigzag arrow: irradiation and blued dotted arrow at
the balance indicates the increase in weight of Tregs expansion.
Either ex vivo or in vivo expanded Tregs (tTreg or pTreg) represent a unique lymphoid population
endowed with cell-intrinsic and cell-extrinsic features to counterbalance the active proliferation of
memory-like cells in lymphopenic environments that predisposes the host to autoimmunity and to
develop greater alloimmune responses. Therefore, the introduction of novel approaches that allow
full reconstitution of the peripheral T cell compartment with sufficient TCR diversity and not prone
to autoimmunity needs more intensive research to manipulate lymphopenia-induced homeostatic
proliferation with therapeutic purposes to either enhance or mitigate immunological responses.
This idea places Tregs at the central stage of current research.
1.3. In Vivo versus in Vitro Tregs Expansion to Modulate Graft Rejection
The number of Treg cells and their suppressive functional activity are of paramount importance
for the maintenance of normal homeostasis of the immune system. The maintenance of Tregs
in vivo depends on CD28 engagement by B7 ligands as demonstrated in B7- or CD28-deficient mice,
which are practically devoid of Tregs [42]. This explains why the administration of soluble CTLA-4.Ig
(a costimulatory blockade molecule that competes with CD28 for binding to B7 molecules) reduces Tregs
cell number in secondary lymphoid organs [43–45]. Indeed, there is an inverse correlation between the
dose of CTLA4.Ig administered and the absolute number of Tregs in both mice and humans [46–48].
In clinical transplantation, nevertheless, the effect of a high-affinity variant of CTLA4.Ig (belatacept) on
Tregs has been difficult to assess because this biologic is administered in combination with blocking
antibodies targeting IL-2Rα and cyclosporine [48,49]. The latter is known to decrease Tregs survival
by blocking IL-2 production. Despite this, it is currently widely accepted that use of high doses of
CTLA4.Ig is detrimental to Treg survival, whereas low doses of CTLA4.Ig, unable to saturate B7,
may favor Tregs expansion to some extent in the long term [46–48].
Another robust costimulatory blockade strategy in transplantation consists of donor-specific
transfusion administered along with anti-CD40L blockade (clone MR1, eliminates recently activated
CD4 T cells transiently expressing CD40L and prevents T cell help to B cells). This approach is
very reproducible and efficient to induce long-term survival of vascularized allografts by inducing T
follicular regulatory cells (Tfr) and tipping the balance of Tregs over effector T cells [5]. Tregs apparently
increase at the expense of depletion of effector CD4 T cells, but not due to expansion, contributing to
modulate T cell mechanisms of rejection [50,51]. When this approach is combined with low doses of
CTLA4.Ig, the survival outcome improves, and immunoregulatory mechanisms seem to be involved
in tolerance induction [46,51,52].
In brief, the co-stimulation blockade by targeting CD28/B7 and CD40/CD40L pathways is still
an unmet clinical reality not comparable with that achieved in preclinical settings. This is in part
because anti-CD40L antibody treatment in non-human primate models was associated with severe
thromboembolism episodes [53]. Future research will provide us with a further understanding on how
to harness these pathways for the benefit of Treg expansion to promote immunoregulatory mechanisms
vital for the induction of transplant tolerance.
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Since the discovery of the co-culture assay of CD4+CD25+ (suppressor) T cells and CD4+CD25-
(effector) T cells, in which the suppressive potency of in vitro derived Tregs could be evaluated by
its ability to prevent effector T cell proliferation [54], an array of experimental approaches has been
implemented so far for the in vitro expansion of Tregs. Although this is not the focus of this review, it is
worth mentioning that, in essence, most Tregs expansion protocols rely on in vitro stimulation of sorted
Tregs displaying the CD4+CD25+CD127- (IL-7Rα) phenotype with polyclonal stimuli that consists
of anti-CD3/anti-CD28 antibodies attached to beads. This is done in the presence of growth factors
such as soluble IL-2 and/or TGF-β, and rapamycin (the latter to prevent parallel expansion of residual
conventional T cells contaminating the cell culture of sorted Tregs) [55,56]. Rapamycin also exhibits an
add-on effect expanding Tregs in vitro [57]. Other drugs, such as epigenetic modifiers 5-azacytidine
(hypomethylating agent) and decitabine (histone deaminase inhibitor), have been applied in HSCT in
an attempt to attenuate GvHD through an epigenetic control of Foxp3 expression in both preclinical
and clinical settings. These pharmacological interventions induce a significant increase in the number
of pTregs associated with decreased GvHD [58,59]. As opposed to in vitro induced Tregs, which are
rather unstable and prone to lose Foxp3 expression and suppressive function after extensive culture
periods, in vivo expansion of Tregs opens up an appealing new window of opportunities in the field of
immunology that deserves more attention in the coming future.
2. Molecules of the Tumor Necrosis Factor (TNF)/TNFR Superfamily Involved in Tregs Expansion
Two main groups of molecules have evolved in the immune system for the maintenance
of its function: immunoglobulin superfamily and TNF/TNFR superfamily. While TNFRs are
primarily expressed on immune cells, their ligands display a broader pattern of expression not
only restricted to immune cells with antigen-presenting function, but also are present in non-immune
cells. TNFR molecules are type I proteins that are differentially expressed on Tregs when compared to
effector/memory T cells, in which expression is usually lower, although this depends on the TNF/TNFR
ligand interaction considered. In contrast, TNF superfamily ligands are type II transmembrane
proteins characterized by a C-terminal TNF homology domain (THD), which promotes assembly of
homotrimeric molecules and binding to TNF receptor superfamily (TNFRSF) receptors. They exist
in two forms: membrane-bound or soluble after proteolytic processing (metalloproteases or other
proteases such as furin) of the stalk region separating the THD from the transmembrane domain.
They behave as soluble cytokines executing their regulatory or inflammatory functions over the course
of the immune response [60–63]. Agonist antibodies against TNFR or agonist ligands used as soluble
fusion recombinant proteins can promote proliferative and survival signals on Tregs. So far, the most
promising targetable molecules to achieve in vivo expansion of Tregs are members of the TNFR
superfamily, TNFR2 and DR3 and their ligands TNF and TL1A, respectively [64–66]. This approach
offers some advantages over previous strategies based on the use of IL-2/anti-IL-2 immune complexes
because a more selective expansion of Tregs can be achieved [64,65,67].
3. Redundant Functional Activity of TNFRSF Members in Tregs Differentiation and Survival
Two signals, signal 1 (TCR/peptide MHC) and signal 2 (CD28/B7), are essential to modulate the
initial phase of T cell activation that prepares T cells for peripheral expansion and cell differentiation
towards effector T cells. As soon as T cells become activated, profound changes occur in the array of
molecules expressed. This response is accompanied by upregulation of cell surface proteins of the
tumor necrosis factor receptor (TNFR) superfamily. The most relevant members of this family with
implications in Tregs expansion are TNFR2 (TNFRSF1B), DR3 (TNFRSF25), glucocorticoid-induced
TNFR-related protein (GITR, TNFRSF18), and OX40 (CD134, TNFRSF4), although in this review we will
center our attention on the two first receptors for their primary implication in in vivo Tregs expansion.
TNFR members independently or collectively work together to promote Tregs precursor differentiation
in the thymus and to maintain Tregs homeostasis and function in the periphery [66,68,69].
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Some members of the TNFR superfamily have been reported to play redundant functions in the life
of Tregs. Loss of function of each of the above-mentioned TNFR members impairs thymic development
and conversion of naïve T cells into peripheral Tregs with suppressive activity. Consequently, Tregs cell
numbers in primary and secondary lymphoid organs are reduced [69]. Whereas the genetic deficiency
(gene KO or tailless dominant negative forms) of one of the TNFR member results in mild reductions
of Tregs cell number, when combined with deficiency of other TNFR members, pTregs counts drop
drastically in these mice because of loss of thymic Tregs production from Tregs precursors [68].
This suggests that loss of one TNFRSF member on Tregs can still be compensated for by the function
of others. However, the loss of multiple receptors or the loss of downstream signaling molecules
they share such as RelA (NF-kB transcription factor) leads to severe defects in Tregs formation in the
thymus that is translated into a paucity of Tregs in the periphery. This finding supports the primordial
function of RelA in Tregs development [70]. In contrast, the transcription factor c-Rel has been shown
to be essential for the efficient induction of Foxp3 in thymic Tregs precursors [69]. This suggests a
division of labor and cooperation in the transcriptional control of different members of the NF-kB
transcription factors in Tregs cell development. Despite the relevance of RelA in Treg development,
this transcription factor has been shown to be dispensable for the differentiation of antigen-specific
CD8+ effector T cells as well as CD4+ type 1 helper (Th1) and follicular T helper (Tfh) cells [69].
In summary, the TNFRSF–NF-kB axis is a non-redundant pathway to maintain Tregs pool constant in
lymphoid and non-lymphoid tissues in both mice and humans.
It has been proposed that upregulation of the TNFR members in the thymus and the observed
greater expression of these receptors on Tregs than on conventional T cells may be related to positive
selection of thymic Tregs. The increased expression of some TNFR members in Tregs cell progenitors
of the thymus and their engagement by their correspondent ligands would provide Tregs with a
competitive survival advantage over non-Tregs to access a limited source of IL-2 growth factor in the
developmental niche of the thymus [69]. These receptors may have a costimulatory effect on Tregs cell
precursors and promote their conversion into mature FoxP3+ Tregs cells in the thymus [68]. All in all,
this would lower the threshold of T cell activation of Tregs that exhibit high-affinity T cell receptors
(TCR) and recognize self-peptide ligands in the context of major histocompatibility complex (MHC)
class II molecules, and would promote their selection [68,71].
4. The Role of TNFR1 and TNFR2 in In Vivo Tregs Expansion
Tumor necrosis factor was first identified and isolated tracking its ability to kill tumor cells in vitro
and induce local hemorrhagic necrosis of transplantable tumors in mice, and for mediating endotoxin
shock when released in large amounts in response to lipopolysaccharide [72]. It is also of primordial
importance in the regulation of leukocyte attachment and migration through the endothelial layer to
the site of inflammation [73]. The first key evidence of the role of TNF in immune-related inflammatory
disorders came from the finding that antibody-mediated blockade of TNF inhibited the synthesis of
pro-inflammatory cytokines such as IL-1, IL-6, and GM-CSF in synovial cell cultures. This discovery
fueled the concept that TNF was at the top of a pro-inflammatory cytokine cascade and enlightened
the path for treatment development [74].
Tumor necrosis factor (TNF) has two receptors, TNFR1 (TNFRSF1A, CD120a) and TNFR2
(TNFRSF1B, CD120b), each one with different pathways of signal transduction [75]. TNF presents two
forms, a membrane-bound form (mTNF that activates both TNFR1 and TNFR2) and a soluble form
that activates TNFR1 only. mTNF can be proteolytically processed into soluble TNF (sTNF) by the
metalloprotease ADAM17. TNFR1 is widely expressed on any type of cell, although undetectable
by flow cytometry on Tregs or conventional T cells. Thus, whereas TNFR1 has ubiquitous cellular
expression, TNFR2 presents a more restricted pattern of expression encompassing conventional
T cells, Tregs, myeloid-derived suppressor cells (MDSCs), endothelial cells, and neurons [76,77].
Most human and mice Tregs express high levels of TNFR2, which is crucial for Tregs proliferation and
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the maintenance of Tregs suppressive function [65,78]. TNFR2+ Tregs are indeed more potent than
TNFR2-deficient Tregs [77,79].
TNFR1, and the closely related receptor DR3, both contain an intracellular death domain (DD)
which, according to structural studies on DR3, can shift from a resting compact fold to an active
elongated fold able to interact with itself and to additionally bind signaling DD-containing proteins
such as TNFR1-associated death domain (TRADD) and RIPK1 [80]. Self-interactions of the DD may
extend receptor oligomerization initiated by ligand binding and explain why TNFR1, but not TNFR2
that lack a DD, can respond to soluble TNF (Figure 3A). TNFR1 and TNFR2 signaling has recently been
reviewed extensively [81]. Briefly, TRADD recruits a TRAF2-containing ubiquitin ligase complex that
modifies RIPK1 with K63-linked ubiquitins, allowing recruitment of a second ubiquitin ligase complex,
LUBAC that further modifies RIPK1 with linear ubiquitin chains to recruit the adaptor proteins TAB2
and NEMO and their associated kinases TAK1 and IKK2. TAK1 activates IKK2, which is at the apex of
the usually pro-inflammatory and pro-survival classical NF-kB signaling pathway (Figure 3B, left part).
The signaling complex can detach from the receptor and replace it with the DD-containing adaptor
Fas-associated death domain (FADD) that, in turn, recruits pro-caspase-8. When NF-kB is active,
FLICE/Caspase 8 inhibitory protein (FLIP) expression is induced, FLIP keeps pro-caspase-8 in check,
and the soluble complex still activates classical NF-kB (Figure 3B, central part). If NF-kB is deficient,
for example by lack of TRAF2-containing ubiquitin ligase complexes, the soluble signaling complex
signals cell death, either by activation of caspase-8 and apoptosis or, in the absence of caspase activity,
by RIPK1-mediated, RIPK3- and MLKL-dependent necroptosis (Figure 3B, right part). TNFR2 has
no intracellular DD and cannot signal cell death directly. When activated by membrane-bound TNF,
TNFR2 directly recruits the TRAF2-containing ubiquitin ligase complex, leading to activation of
classical NF-kB (Figure 3C, left part). This also activates the alternative NF-kB signaling pathway,
as the ubiquitin ligase complex is not available anymore to target, via TRAF3, the kinase NIK for
proteasomal degradation. NIK accumulates and activates IKK1 at the apex of alternative NF-kB
signaling (Figure 3C). Depletion of TRAF2-containing ubiquitin ligase complex on TNFR2 can also
divert TNFR1 signaling from NF-kB to cell death (Figure 3B) [81]. In Tregs, the net effect of TNFR2
signaling is to reinforce expression of signature genes (FoxP3, CTLA-4, CD25, and GITR) and the
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formation (bi-directional arrow) that would explain responsiveness to soluble ligands. DD-containing
proteins TRADD and RIPK1 are also recruited to activated DD. Model based on Yin et al. 2019 [80].
(B) TNFR1 receptor-interacting signaling complex and its derived soluble signaling complexes.
Successive recruitment of two ubiquitin ligases complexes to TNFR1 allows ubiquitination of RIP1
(K63-linked and linear poly-ubiquitin) to recruit TAK1 and IKK2 for the activation of MAPK and
classical NF-kB. Unlike what happens in other death receptors, the adapter FADD is not recruited to
TNFR1. The signaling complex must first dissociate from receptors as a cytosolic complex to bind FADD
and pro-caspase-8. If pro-caspase-8 is inhibited by FLICE/Caspase 8 inhibitory protein (FLIP), cell death
is not induced. If NF-kB is impaired, active caspase-8 is produced, which processes RIPK1 to an inactive
form and induces apoptosis. If caspases are inhibited, RIPK1 is not cleaved and induces necroptosis
via RIPK3 and MLKL. Model based on the review of Wajant and Siegmund [81]. (C) Signaling by
TNFR2. TNFR2 activates classical NF-kB by a mechanism similar to that of TNFR1, except that the
DD-containing proteins TRADD and RIPK1 are not implicated. As the ubiquitin ligase that targets NIK
for degradation in the resting state is recruited to TNFR2 upon signaling, NIK escapes degradation
and stimulates alternative NF-kB signaling via IKK1. Model based on Wajant and Siegmund [81].
(D) Graphical legend for signaling components depicted in panels A, B, and C.
5. Evidence of the Anti-Inflammatory Functions of TNF and Its Role in Tregs Function
Apart from the predominant proinflammatory function of TNF, multiple sources support an
anti-inflammatory role of this cytokine in chronic infections and in the chronic phase of many
inflammatory diseases [83]. One of the first compelling indications of the impact of TNFR2 in Tregs
biology was that TNFR2-deficient mice exhibited a reduction in Tregs cell number in both the thymus and
secondary lymphoid organs [84]. This phenotype was similar to that seen in mice that are triple-knockout
for the three known (human) TNFR2 ligands: TNF, lymphotoxin-α, and lymphotoxin-β [78], of which
TNF might be the most relevant due to the fact that only mouse TNF binds to mouse TNFR2 [85].
Mice knock-in for human TNF, which unlike mouse TNF does not bind to mouse TNFR2, have a
decreased Treg function, unless they are also knock-in for human TNFR2. Specific ablation of
TNFR2 in Tregs did not decrease their numbers but diminished expression of signature genes and
impaired suppressive activity in vitro, and in vivo in an experimental autoimmune encephalitis model,
directly demonstrating a critical intrinsic role of TNFR2 to maintain the functionality of Treg cells [82].
Further evidence links TNFR2 with Tregs function because co-transfer of TNFR2-deficient Tregs
along with naïve CD4 T cells into immunodeficient Rag1 KO recipient mice did not prevent colitis
development [78]. Whereas Tregs are capable to suppress in vivo IL-6 production in response to
LPS injection, Tregs from TNFR2-deficient mice failed to do so, although they could still suppress
T cell proliferation in the gold standard in vitro co-culture suppression assay [65]. This correlates
with the fact that both mouse and human peripheral Tregs expressed remarkably higher surface
levels of TNFR2 than non-Tregs, irrespective of their resting or activated status, whereas TNFR1 is
barely detectable on T cells or Tregs cells [65]. Another hint in the track for the identification of
the regulatory role of TNFR2 came from the observation that polymorphisms of TNFR2 were often
associated with increased inflammation in chronic autoimmune diseases and in GvHD (the latter
being a common adverse effect of allogeneic bone marrow transplantation) [86]. Moreover, patients
with chronic autoimmune diseases or chronic GvHD that were refractory to first-line treatment with
steroids and to second-line treatment with TNF blockers, etanercept (TNF decoy receptor) or infliximab
(chimeric recombinant anti-TNF antibody), sometimes suffered from worsened symptoms [87]. In the
same line of evidence, chronic inflammatory illness and late stages of infection are more severe in
TNF-deficient mice than in WT mice [83]. Globally, these findings suggest that blockade of TNF in
the chronic phase of the inflammatory response could interfere with natural regulatory mechanisms
necessary to halt disease progression.
In vitro studies of Tregs expansion in the presence of IL-2 and proinflammatory cytokines
(i.e., TNF) have also contributed to gain insight into the role of TNF on Tregs function. Although some
in vitro studies of Tregs exposure to TNF claimed that this cytokine interfered with Tregs suppressive
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function [88,89], other authors support the notion of beneficial effects on Tregs. In this regard, TNF was
shown to stimulate in vitro proliferation and expansion of human Tregs that exhibited enhanced
suppressive capacity and more stable phenotype [68,90]. Despite these conflicting data, the current
consensus is that TNF plays a positive role in Tregs function. These contradictory data might be due,
at least in part, to different proportions of aggregates in TNF preparations that would result in different
signaling abilities.
The overall effect of TNF on Tregs seems to be mediated by signaling through TNFR2, which is
highly expressed on both human and mouse Tregs when compared to conventional T cells [65,76,91].
6. Role of TNFR2 in Tregs Expansion in Allogeneic Bone Marrow Transplantation and
Cardiac Transplantation
The adoptive transfer of donor-derived Tregs to conditioned recipient mice attenuates the severity
of graft-versus-host disease (GvHD) in different settings of allogeneic bone marrow transplantation
across distinct MHC histocompatibility barriers [92,93]. Co-administration of in vitro expanded Tregs
stimulated via the direct or indirect antigen presentation pathways at the time of bone marrow
transplantation induces transplantation tolerance to skin and heart transplants of the same haplotype
and protects them against acute and chronic rejection [94].
In the field of transplantation research, the most convincing data on the role of TNFR2 in Tregs
expansion comes from three simultaneous studies in 2016 that took advantage of experimental mouse
models of allogeneic bone marrow transplantation across distinct MHC barriers. In one of the
studies, Chopra et al. developed a nonameric TNF complex with selective agonist activity on TNFR2,
termed STAR2. This compound was composed of three covalently linked TNF trimers in which TNF
monomers were mutated to selectively abrogate binding to TNFR1. They used this biological molecule
to treat lethally irradiated recipients with the purpose to expand residual Tregs before performing
allogeneic bone marrow transplantation across an MHC class I barrier (Figure 4A). This treatment
attenuated the course of GvHD, and the effect was abolished in TNFR2-deficient recipient mice or
in Tregs-depleted recipient mice [95]. Leclerc et al. demonstrated, in a semiallogeneic bone marrow
transplant setting, that TNFR2 expression on donor adoptively transferred Tregs was essential to
mediate their immunosuppressive effect, and that the source of TNF to stimulate TNFR2 comes from
allogeneic T cells co-transferred with the bone marrow transplant. Thus, blockade of TNFR2 with an
antagonist antibody or the use of TNFR2-deficient Tregs could not modulate GvHD [96] (Figure 4B).
Finally, Pierini et al. used an allogeneic bone marrow transplant mouse model across a full MHC
mismatched barrier. The approach consisted of the adoptive transfer of preconditioned donor-type
Tregs that were in vitro exposed to irradiated peripheral blood cells from acute GvHD recipients
(cytokine primed) or primed with TNF in the presence of IL-2. This preconditioning of donor Tregs
prevented GvHD at an unfavorable Tregs/allogeneic T cells ratio (1:10), while unprimed Tregs did not
confer protection to GvHD [97] (Figure 4C).
In solid organ transplantation, the number of studies is still scarce. It is worth mentioning one
study that implicated TNF in chronic rejection of heart allografts [98]. One of the pathognomonic
signs of cardiovascular chronic allograft rejection is the thickening of the intimal layer of the artery,
a lesion composed of smooth muscle cells and extracellular matrix, along with immune cells infiltration
produced in response to steady-state inflammation. Lack of both TNFR1 and TNFR2 on the endothelium
of donor hearts attenuates graft vascular disease [98].
In conclusion, these data point to the fact that TNFR2 is a promising targetable molecule for
the expansion of donor or recipient Tregs that display functional suppressive activity to modulate
the course of GvHD across distinct histocompatibility barriers and to mitigate the process of chronic
rejection of vascularized allografts.
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expansion in allogeneic bone marrow transplantation across different histocompatibility barriers.
(A) Chopra et al. ade use of a multi eric reco binant TNFR2 agonist, termed STAR2 containing
mutations, to prevent binding to TNFR1. They demonstrated that pretreatment of irradiated recipients
with STAR2 peri-transplant expanded residual Tregs that attenu t d GvHD and prolonged host
survival. This protective effect was aboli hed in TNFR2-deficient r cipient mice and in recipient mice
depleted of Tregs [95]. (B) Leclerc at al. demonstrated that TNFR2-deficient Tregs or antibody-me iated
blockade of TNF/TNFR2 did not abolish the protective effect of Tregs on GvHD. Tregs functional activity
depended on TNF production by conventional T cells co-transferred with the allogeneic bone marrow
transplant [96]. (C) Pierini et al. showed that the preconditioning of donor-type Tregs ex-vivo with
irradiated host peripheral blood undergoing acute GvHD (cytokine-primed) or primed with TNF in the
presence of IL-2 attenuated GvHD at an unfavorable Tregs: T conventional ratio (1:10) [97]. In contrast,
unprimed Tregs did not confer protection to GvHD development in a setting of allogeneic bone marrow
transplantation across a fully MHC mismatched barrier.
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7. TL1A (TNFSF15)/DR3 (TNFRSF25) Pathway
The TNFRSF member termed death receptor 3 (DR3, TNFRSF25) is a type I transmembrane protein
with homology to TNFR1 [60]. DR3 engagement by its ligand TL1A (TNFSF15) mediates NF-kB,
MAP kinase, and caspase signaling that regulates cell activation, proliferation, and differentiation,
but also modulates apoptosis in immune cells [99]. Death receptor 3 is readily inducible upon exposure
to allogeneic stimuli on both CD4 T cells (Tregs and non-Tregs) and on CD8 T cells. Apart from T cells,
NKT cells and innate lymphoid cells also express DR3. It is also present to a lower extent in B cells,
monocytes, and macrophages. In contrast, TL1A, the ligand of DR3 receptor, presents a pattern of
expression restricted to antigen-presenting cells (dendritic cells) and endothelial cells [100,101].
DR3 (TNFRSF25) was initially claimed to be preferentially expressed on Tregs and only barely
on resting T cells [64]. This notion generated certain controversy in the field that stemmed from the
existence of two alternative DR3 mRNA splicing variants and different anti-DR3 hybridoma clones.
DR3 variant 1, with an extracellular region exhibiting four cysteine-rich domains, a transmembrane
region, and an intracellular region and DR3 variant 3, which lacks cysteine-rich domain 4 in the
extracellular region [64,102]. This controversy unleashed a debate that was resolved with the
introduction of a novel monoclonal anti-DR3 antibody. This new reagent identified a common epitope
on DR3 of Tregs and conventional T cells, concluding that both cell types expressed a similar amount
of DR3 on their cell surface at their resting state. The amount of DR3 increased in both cell types
upon activation [102].
The expansion of Tregs upon DR3 engagement was first described in a mouse model of allergy.
In this model, the administration of anti-DR3 agonist antibody (clone 4C12) or soluble TL1A.Ig
recombinant fusion protein (soluble DR3 agonist) stimulated a transient expansion of Tregs. This agonist
activity was modestly increased by the addition of IL-2 immunocomplexes (IL-2/anti-IL-2) [64].
Taking advantage of the knowledge gathered from mouse models of allergy, in vivo expansion of
donor Tregs with agonist anti-DR3 antibody was achieved before bone marrow cells were harvested
for the transplant. This intervention permits the enrichment of donor Tregs in the bone marrow
inoculum that would contribute to mitigate the pathogenic impact of donor anti-host alloreactivity [103].
The expansion of Tregs can also be achieved in pre-conditioned recipient mice, but the treatment
with anti-DR3 antibody has to be interrupted soon after allogeneic bone marrow transplantation.
Once donor anti-host response is initiated and donor T cells become activated, anti-DR3 treatment
may trigger undesirable side effects due to co-stimulation of donor alloreactive T cells. This would
exacerbate the course of the GvHD and overcome the initial beneficial anti-inflammatory effects of
Tregs [104,105]. In any case, this strategy is still awaiting translational application in humans because,
currently, anti-human DR3 agonist antibodies are not yet available for the clinic.
In the setting of heart allogeneic transplantation, treatment with agonist anti-DR3 antibody
(clone 4C12) resulted in expansion of Tregs Foxp3+ to 30–35% of gated CD4+ cells. This increase in
Tregs was associated with a significant graft prolongation from day 8 to day 17 that correlated
with accumulation of Foxp3+ Tregs within the graft and a significant reduction of infiltrating
inflammatory cells [106].
In summary, DR3 is a targetable receptor that permits the preferential expansion of donor Tregs or
residual host Tregs that remain after host conditioning. Anti-DR3 treatment should be implemented
before donor anti-host alloreactive T cells become activated.
8. Concluding Remarks on the Therapeutic Implication of Targeting TNFR in Inflammatory Diseases
Etanercept (TNF decoy receptor) and infliximab (chimeric anti-TNF antibody) are two examples
of the most common TNF blockers approved for clinical use as a second line for the treatment of
steroid-refractory GvHD and autoimmune diseases either alone or in combination with methotrexate;
however, some patients do not respond, and disease can be exacerbated upon TNF blockade.
This undesirable outcome may be the result of inhibition of Tregs suppressive function that prevents
membrane-bound TNF binding to TNFR2.
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To overcome these hurdles, there is an emerging interest in the development of recombinant
biological compounds that can target specifically TNFR2 without engaging TNFR1, to expand
in vivo Tregs and potentiate their beneficial modulatory effect on the course of inflammation [95,107].
Considering that selective neutralization of TNF/TNFR1 signaling is beneficial in several inflammatory
diseases, if this could be combined with TNFR2 agonist compounds, a reinforcement of
current treatments may be accomplished to attenuate inflammatory diseases and graft rejection.
Mutated versions of oligomerized TNF compounds such as STAR-2 (multimeric mutated TNF soluble
fusion protein with binding specificity for only TNFR2) or fully/partially agonist non-depleting
antibodies targeting TNFR2 anchored to cell surfaces or through FcγR are capable to engage TNFR2
and stimulate Tregs function. This stimulatory outcome occurs despite antibodies exhibiting low
affinity and regardless of the location of epitope within the molecule [108]. The use of TNFR agonists
in patients undergoing T cell-depleted induced-lymphopenia with the purpose of tipping the balance
of Tregs over conventional T cells during the course of immune reconstitution in transplant patients
would be a pertinent approach to limit long-term administration of immunosuppression and modulate
the course of graft rejection or GvHD.
One consideration that should be kept in mind arises from the fact that T cell activation upregulates
most TNFR members in both Tregs and conventional T cells, and the engagement of these receptors
can contribute to co-stimulation. This co-signal effect would enhance T cell cytotoxic activity or would
make effector T cells more resistant to Tregs-mediated suppression [91]. A sense of caution should,
however, accompany future clinical trials to prevent co-stimulation of donor anti-host alloreactive T
cells, once they are activated, to prevent worsening of the disease. Therefore, the timing for antibody
administration in the approved protocol should be finely tuned.
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Abbreviations
FLIP FLICE/Caspase 8 inhibitory protein
LIP Lymphopenia-induced proliferation
tTregs thymic regulatory T cells
pTregs peripheral regulatory T cells
TCR T cell receptor
rATG rabbit polyclonal anti-thymocyte globulin
MHC major histocompatibility complex
TNFR tumor necrosis factor receptor
Alemtuzumab chimeric recombinant antibody against CD52
IL-2 interleukin 2
IL-7 interleukin 7
LIP Lymphopenia-induced proliferation
THD TNF homology domain
Tregs regulatory T cells
TCD T-cell depleted
TNF Tumor necrosis factor
TGF-β Tumor growth factor
TNFRSF TNF receptor superfamily
Foxp3 Forkhead box P3 transcription factor
AIRE Autoimmune regulator
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TCR T cell receptor
MHC Major histocompatibility complex
GvHD Graft versus Host Disease
tTregs thymic Tregs
pTregs Peripheral Treg
CTLA-4 (CD152) Cytotoxic T-Lymphocyte-Associated protein 4
IDO Indoleamine 2,3-dioxygenase
LAP Latency-Associated Protein
ATP Adenosine triphosphate
ADP Adenosine diphosphate
AMP Adenosine monophosphate
rATG rabbit anti-thymocyte globulin
MAPK Mitogen-activated protein kinase
FADD Fas-associated death domain adaptor proteins
TRADD TNFR1-associated death domain
MDSC Myeloid-derived suppressive cells
IL-2 Interleukin 2
DR3 Death receptor 3
HSCT Hematopoietic stem cell transplantation
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells
GM-CSF Granulocyte/monocyte-colony stimulating factor
IPEX Immunodysregulation polyendocrinopathy and enteropathy X-linked
MHC major histocompatibility complex
BMTx bone marrow transplantation
TNFKO tumor necrosis factor knock-out
STAR2 Multimeric TNFR2 agonist
GvHD graft versus-host reaction
TNFR2 tumor necrosis factor 2
IL-2 interleukin 2
TCD T cell-depleted
Tregs regulatory T cells
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